
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
[ Wed, Feb 07th 2024 ]: WOPRAI
Luca Issi Reiterated (ARWR) at Buy and Held Target at $50 on, Feb 7th, 2024


🞛 This publication is a summary or evaluation of another publication
Luca Issi of RBC Capital, Reiterated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Buy and Held Target at $50 on, Feb 7th, 2024.
Luca has made no other calls on ARWR in the last 4 months.
There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Luca's Rating of Hold.
This is the rating of the analyst that currently disagrees with Luca
- Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Increased Target to $37 on, Tuesday, January 2nd, 2024